ALPHA-SYNUCLEIN, SNCA, ELISA KIT; 125pg/ml sensitivity (a-synuclein, alpha synuclein elisa; Part h,m,r hsnca, 96T) kw SNCA, alpha synuclein, synuclein, a-synuclein)

• Separate kits are  available for human, mouse and rat alpha-synuclein.
  
• Pre-configured ELISA kit in sandwich assay format: 96T.
  
• 200pg/ml - 100ng/ml  Dynamic Assay Range for Human SNCA: .  Sensitivity: 125pg/ml for human alpha-synuclein.
  
• One step incubation for 60min at 37^oC.  Samples are mixed with biotin labelled detected antibody and streptavidin-HRP and are then added to the ELISA plate that is provided pre-coated with an anti-alpha-synuclein monoclonal antibody.
  

---

Protocol

Methods Overview:

1. Mix sample, biotinylated-detection antibody and streptavidin-HRP.
2. Apply sample and antibody-HRP complex to ELISA plate for 60min at 37^oC.  Wash 5 times.
3. Apply chromogen incubate, then stop reaction.

Introduction to Alpha-Synuclein:   Alpha-synuclein (SNCA gene) is a 140 amino acid  protein expressed in brain that is associated with fibrillar structures in Lewy Bodies.  Although primary located in the cytosol, alpha-synuclein binds to phospholipid and may assemble into pore-like structures in cellular membranes.  Generation of aggregates in Lewy Bodies and/or association of mutant or wild-type alpha-synuclein with membraneous structures have been attributed to the etiology of both early-onset congenital and age-related Parkinson’s Disease. 

Parkinson's disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability.  Additional features of the disease include the characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies in brain and spinal cord. 

1. Adamczyk, A. et al. (2007) Alpha-synuclein decreases arachidonic acid incorporation into rat striatal synaptoneurosomes. Folia Neuropathol 45 (4), 230-235
2. Kim, H.J. et al. (2007) Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment. J Microbiol Biotechnol 17 (12), 2027-2032
3. Wakabayashi, K. et al. (2007) The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27 (5), 494-506
4. Yoshida, M. (2007) Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 27 (5), 484-493
5. Kloepper, K.D. et al. (2007) Solid-state NMR spectroscopy reveals that water is nonessential to the core structure of alpha-synuclein fibrils. J Phys Chem B 111 (47), 13353-13356
6. Buchman, V.L. and Ninkina, N. (2008) Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze? Neurotox Res 14 (4), 329-341
7. Fuchs, J. et al. (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. Faseb J 22 (5), 1327-1334
8. Parihar, M.S. et al. (2009) Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol 41 (10), 2015-2024
9. Gibrat, C. et al. (2009) Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 109 (5), 1469-1482